Savara Inc. (NASDAQ:SVRA) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Savara Inc. (NASDAQ:SVRA) has earned an average recommendation of “Moderate Buy” from the ten brokerages that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, seven have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $9.1250.

A number of research analysts have recently weighed in on the company. UBS Group set a $10.00 price target on Savara in a report on Tuesday, December 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a research report on Thursday, January 22nd. Oppenheimer set a $10.00 target price on Savara in a report on Tuesday, December 23rd. Wells Fargo & Company raised their price target on shares of Savara from $7.00 to $9.00 and gave the stock an “overweight” rating in a report on Thursday, December 18th. Finally, Lifesci Capital raised shares of Savara to a “strong-buy” rating in a research report on Tuesday, October 14th.

Savara Stock Down 5.3%

SVRA stock opened at $5.36 on Thursday. The company has a debt-to-equity ratio of 0.32, a current ratio of 7.65 and a quick ratio of 7.65. The firm has a market capitalization of $1.09 billion, a P/E ratio of -10.11 and a beta of 0.34. Savara has a 52-week low of $1.89 and a 52-week high of $7.01. The company’s 50 day simple moving average is $6.05 and its 200-day simple moving average is $4.43.

Savara (NASDAQ:SVRA) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). As a group, equities research analysts anticipate that Savara will post -0.45 EPS for the current year.

Hedge Funds Weigh In On Savara

Hedge funds have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. boosted its position in Savara by 48.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,887 shares of the company’s stock valued at $60,000 after purchasing an additional 3,205 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of Savara by 930.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock valued at $37,000 after buying an additional 9,463 shares during the last quarter. CIBC Bancorp USA Inc. bought a new stake in shares of Savara in the 3rd quarter valued at approximately $44,000. Prudential Financial Inc. acquired a new position in Savara in the second quarter worth approximately $30,000. Finally, BNP Paribas Financial Markets increased its holdings in Savara by 52.3% in the second quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock worth $31,000 after buying an additional 4,626 shares during the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.